JP2024512767A5 - - Google Patents
Info
- Publication number
- JP2024512767A5 JP2024512767A5 JP2023560831A JP2023560831A JP2024512767A5 JP 2024512767 A5 JP2024512767 A5 JP 2024512767A5 JP 2023560831 A JP2023560831 A JP 2023560831A JP 2023560831 A JP2023560831 A JP 2023560831A JP 2024512767 A5 JP2024512767 A5 JP 2024512767A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- membered
- alkyl
- hydrogen
- bonded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163170292P | 2021-04-02 | 2021-04-02 | |
| US63/170,292 | 2021-04-02 | ||
| US202163192843P | 2021-05-25 | 2021-05-25 | |
| US63/192,843 | 2021-05-25 | ||
| PCT/US2022/023133 WO2022212894A1 (en) | 2021-04-02 | 2022-04-01 | Methods for inhibiting ras |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024512767A JP2024512767A (ja) | 2024-03-19 |
| JP2024512767A5 true JP2024512767A5 (cg-RX-API-DMAC7.html) | 2025-04-08 |
Family
ID=83456876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560831A Pending JP2024512767A (ja) | 2021-04-02 | 2022-04-01 | Rasの阻害方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240108630A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4320143A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024512767A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240004436A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022249177A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023020182A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3214155A1 (cg-RX-API-DMAC7.html) |
| CR (1) | CR20230500A (cg-RX-API-DMAC7.html) |
| IL (1) | IL307396A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023011608A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202308632A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022212894A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023199180A1 (en) * | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
| WO2023232776A1 (en) * | 2022-06-01 | 2023-12-07 | F. Hoffmann-La Roche Ag | Haloindole macrocyclic compounds for the treatment of cancer |
| CN117720555B (zh) * | 2022-09-19 | 2026-05-05 | 杭州阿诺生物医药科技有限公司 | 一种制备kras抑制剂化合物的中间体及其合成方法 |
| CN117903169A (zh) * | 2022-09-19 | 2024-04-19 | 杭州阿诺生物医药科技有限公司 | 一种pan-KRAS抑制剂化合物 |
| EP4596552A1 (en) | 2022-09-29 | 2025-08-06 | Guangzhou Joyo Pharmatech Co., Ltd | Macrocyclic derivative and use thereof |
| CN118047799A (zh) * | 2022-11-16 | 2024-05-17 | 杭州阿诺生物医药科技有限公司 | 一种pan-KRAS抑制剂化合物 |
| CN117534684A (zh) * | 2022-11-29 | 2024-02-09 | 杭州阿诺生物医药科技有限公司 | 一种pan-KRAS抑制剂化合物 |
| EP4661887A1 (en) * | 2023-02-06 | 2025-12-17 | Bicara Therapeutics Inc. | Combination therapy and related methods |
| PE20252395A1 (es) | 2023-02-14 | 2025-10-10 | Hoffmann La Roche | Compuestos triciclicos para el tratamiento de cancer |
| WO2024187174A2 (en) * | 2023-03-09 | 2024-09-12 | Aadigen, Llc | Compositions for treating cancer with kras mutations and uses thereof |
| CN121487738A (zh) * | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| WO2025006967A1 (en) | 2023-06-30 | 2025-01-02 | Bristol-Myers Squibb Company | Kras inhibitors |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| CN121843944A (zh) * | 2023-09-06 | 2026-04-10 | 劲方医药科技(上海)股份有限公司 | 大环化合物及其抗体-药物偶联物 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025087431A1 (zh) * | 2023-10-27 | 2025-05-01 | 贝达药业股份有限公司 | 泛-kras抑制剂及其在医药上的应用 |
| WO2025093625A1 (en) * | 2023-11-01 | 2025-05-08 | F. Hoffmann-La Roche Ag | Macrocycle compounds for the treatment of cancer |
| IL328671A (en) * | 2023-12-08 | 2026-07-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Macrocyclic compound containing an amide substituent |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025193628A2 (en) * | 2024-03-09 | 2025-09-18 | Aadigen, Llc | Compositions for treating cancer with kras mutations and uses thereof |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025252241A1 (zh) * | 2024-06-07 | 2025-12-11 | 杭州和正医药有限公司 | 一种大环衍生物及其用途 |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015745A1 (en) * | 2024-07-11 | 2026-01-15 | Treeline Biosciences, Inc. | Macrocyclic ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101602876B1 (ko) * | 2014-07-22 | 2016-03-11 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
| IL317393A (en) * | 2018-12-21 | 2025-02-01 | Revolution Medicines Inc | Compounds that participate in covalent bonds and their uses |
| CN121471132A (zh) * | 2019-11-04 | 2026-02-06 | 锐新医药公司 | Ras抑制剂 |
| MX2022005359A (es) * | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| WO2021091956A1 (en) * | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| IL301298A (en) * | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
-
2022
- 2022-04-01 CR CR20230500A patent/CR20230500A/es unknown
- 2022-04-01 JP JP2023560831A patent/JP2024512767A/ja active Pending
- 2022-04-01 AU AU2022249177A patent/AU2022249177A1/en active Pending
- 2022-04-01 TW TW111112802A patent/TW202308632A/zh unknown
- 2022-04-01 KR KR1020237037749A patent/KR20240004436A/ko active Pending
- 2022-04-01 EP EP22782324.2A patent/EP4320143A4/en active Pending
- 2022-04-01 BR BR112023020182A patent/BR112023020182A2/pt unknown
- 2022-04-01 WO PCT/US2022/023133 patent/WO2022212894A1/en not_active Ceased
- 2022-04-01 IL IL307396A patent/IL307396A/en unknown
- 2022-04-01 MX MX2023011608A patent/MX2023011608A/es unknown
- 2022-04-01 CA CA3214155A patent/CA3214155A1/en active Pending
-
2023
- 2023-10-02 US US18/479,500 patent/US20240108630A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024521774A5 (cg-RX-API-DMAC7.html) | ||
| CN110003204B (zh) | 一种bet蛋白抑制剂、其制备方法及用途 | |
| JP2026041825A (ja) | 固体形態 | |
| Chiyanzu et al. | Design, synthesis and anti-plasmodial evaluation in vitro of new 4-aminoquinoline isatin derivatives | |
| ES2387270T3 (es) | El archivo contiene la información técnica propuesta después de la presentación de la solicitud y no se incluye en esta especificación | |
| DK2924034T3 (en) | PHARMACEUTICAL COMPOSITION CONTAINING A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | |
| Patel et al. | Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle | |
| JP2024521920A5 (cg-RX-API-DMAC7.html) | ||
| JP7274765B2 (ja) | フェニルトリアゾールmll1-wdr5タンパク質間相互作用阻害剤 | |
| JP2018530594A (ja) | 新規な化合物であるyap/taz−tead相互作用阻害剤、および悪性中皮腫の治療でのその使用 | |
| CN119528810A (zh) | 喹啉类化合物及其应用 | |
| WO2017167182A1 (zh) | 一种选择性的c-kit激酶抑制剂 | |
| JP2010512358A (ja) | スルホンアミドならびに薬剤としてのその使用 | |
| CN105579449A (zh) | 新的用作nampt抑制剂的吡啶基氧基乙酰基四氢异喹啉化合物 | |
| CN108101890A (zh) | N-磺酰基吡咯衍生物 | |
| TW200301698A (en) | Acridone inhibitors of IMPDH enzyme | |
| TW202313048A (zh) | 組合療法 | |
| KR20070112400A (ko) | 신규의 hsp90 저해제 | |
| BR122022005149B1 (pt) | Compostos com atividade anticâncer, composição farmacêutica que os compreende e seus usos | |
| Ghomashi et al. | Recent advances in biological active sulfonamide based hybrid compounds part A: Two-component sulfonamide hybrids | |
| JP2012512887A5 (cg-RX-API-DMAC7.html) | ||
| JP2009537546A5 (cg-RX-API-DMAC7.html) | ||
| ES2300775T3 (es) | Furazanobencimidazoles. | |
| TW200812970A (en) | Inhibitors of AKT (protein kinase B) | |
| CN103193691A (zh) | 磺胺类化合物、药物组合物及其制法和应用 |